News

Researchers reveal that retinal microvasculature analysis via OCTA may enhance noninvasive cardiovascular risk assessment, potentially improving coronary artery stenosis detection.

Andrew G. Lee, MD, shares essential insights on neuro-ophthalmology for retina specialists, emphasizing diagnosis techniques and collaboration with neuro-ops.

Dilsher S. Dhoot, MD, FASRS, shares insights on avoralstat, a promising treatment for diabetic macular edema, at ASRS 2025.

Topcon Healthcare enhances its connected care model by acquiring IRIS, integrating AI for improved diabetic eye disease screening and patient coordination.

EyePoint Pharmaceuticals completes enrollment for the LUCIA trial, advancing DURAVYU's potential as a new treatment for wet AMD.

Opus Genetics partners with the Global RDH12 Alliance to advance gene therapy for inherited retinal disease, aiming for FDA application by late 2025.

Notably, Alcon will be providing a demo of the UNIPEXY Gas Delivery System.

EYLUXV, a new biosimilar for treating serious eye conditions, gains positive EMA recommendation, promising improved patient access and outcomes.

In preparation for the American Society of Retina Specialist (ASRS) annual meeting being held in Long Beach, California, Modern Retina spoke with Gaurav Shah MD, FASRS, Program Chair of the 2025 event.

Re-Vana Therapeutics and Boehringer Ingelheim forge a $1 billion partnership to develop innovative extended-release therapies for eye diseases, enhancing patient care.

Discover groundbreaking findings on oral gildeuretinol's impact on Stargardt disease at the ASRS 43rd Annual Meeting in Long Beach, California.

Australian researchers highlighted the overlooked ocular risks surfers and divers face from UV and blue light exposure.

Vonaprument has received fast track designation from the US Food and Drug Administration.

ANI Pharmaceuticals releases results for ILUVIEN in treating diabetic macular edema.

Catch up on this week's highlights in retina.

Findings from a phase 2 clinical trial support the therapeutic potential of ADX-2191 in patients with retinitis pigmentosa.

The phase 3 ARCHER II trial completes enrollment for vonaprument, targeting vision preservation in dry AMD, with results expected in 2026.

The platform, developed by University College London and Heidelberg Engineering, demonstrated accuracy and precision in early tests.

Kiora Pharmaceuticals secures a patent for KIO-104, enhancing treatment options for ocular diseases and extending market exclusivity until 2043.

OpenAI's ChatGPT-4o enhances ophthalmological image generation, producing realistic retinal photographs while highlighting the need for further research in training datasets.

Ocular Therapeutix to showcase its drug delivery solutions at upcoming ophthalmology conferences.

Mucormycosis emerges as a critical concern in diabetic patients with sudden vision loss, highlighting the need for prompt diagnosis and treatment.

Catch up on this week's highlights in retina.

AAVB-039 advances gene therapy for Stargardt disease, aiming for innovative treatments for inherited retinal disorders.

Sanofi's SAR446597 receives FDA fast track designation, offering a promising one-time gene therapy for geographic atrophy and reducing treatment frequency.

The survey shows the evolving landscape of nAMD and DME treatments, highlighting physician preferences, payer influences, and the promise of gene therapy advancements.

Presentation highlights include 48-month data from the OAKS and DERBY trials as well as the GALE open-label extension.

New tariffs threaten the optical industry, prompting urgent reevaluation of sourcing strategies and pricing as deadlines approach for affected countries.